Publication | Closed Access

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Tumor ImmunologyCancer ImmunosurveillanceMedicineMelanomaImmunologyImmunoeditingImmune Checkpoint InhibitorStage Iii MelanomaImmunotherapeuticsAdjuvant TherapyDermatologyImmunotherapyOncologySkin Cancer